Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

View Full Paper
Ask AI
Bookmark
Share

Authors

RFRongfeng FuChinese Academy of Medical Sciences & Peking Union Medical CollegeZSZonghong ShaoTianjin Medical University General HospitalJBJie BaiChinese University of Hong Kong

Discussion

Loading...

Member takes

Implication

Phase 2 trial shows ropeginterferon improves remission rates in hydroxyurea-intolerant polycythemia vera patients, indicating a favorable safety profile.

Key Points

  • To evaluate the long-term efficacy and safety of ropeginterferon alfa-2b in patients with polycythemia vera.
  • Phase 2, multicenter, single-arm trial
  • Evaluated HIDAT regimen in hydroxyurea-intolerant PV patients
  • Followed 49 patients for 36 months of treatment
  • 75% of patients maintained complete hematologic remission after 24 months
  • Median JAK2V617F VAF reduced significantly from 61.2% to 4.9% after 36 months
  • Event-free survival was 100% in patients achieving complete molecular response

Cite This Study

Fu et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d780https://doi.org/10.1182/blood-2025-2039
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Complete Hematological Response Coupled with Molecular Response in Polycythemia Vera Treatment with Ropeginterferon Alfa-2b2026
  2. 2Long-term outcomes of ropeginterferon alfa-2b-njft in polycythemia vera: a review of safety, efficacy, and potential disease modification2026
  3. 3Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment2024 · 26 citations
  4. 4Hematologic and molecular response to ropeginterferon alfa-2b in patients with polycythemia vera: a systematic review and meta-analysis2026
  5. 5Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera2025